RecruitingPhase 2NCT07534033

Phase II Clinical Study of Probiotic LR607 in Patients With Non-Small Cell Lung Cancer

Studying Wiskott-Aldrich syndrome

Last synced from ClinicalTrials.gov May 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Zhujiang Hospital
Intervention: Probiotics combined with neoadjuvant chemoimmunotherapy(drug)
Enrollment: 46 target
Eligibility: 18-80 years · All sexes
Timeline: 2025 – 2027

Study locations (1)

Zhu Jiang Hospital of Southern Medical University, Guangzhou, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07534033 on ClinicalTrials.gov

Other trials for Wiskott-Aldrich syndrome

Additional recruiting or active studies for the same condition.

ACTIVE NOT RECRUITINGPHASE3NCT03837483
A Clinical Study to Evaluate the Use of a Cryopreserved Formulation of OTL-103 in Subjects With Wiskott-Aldrich Syndrome
Fondazione Telethon
ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT02333760
Long Term Safety Follow up of Haematopoietic Stem Cell Gene Therapy for the Wiskott Aldrich Syndrome
Genethon

See all trials for Wiskott-Aldrich syndrome →

← Back to all trials